Drug Trial Radar · NCT06427811
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Nov 28, 2024
Primary completion
Mar 18, 2026
Study completion Mar 18, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) per the India Prescribing Information (PI). The purpose of this prospective, multicenter, single-arm, open-label, Phase IV study is, therefore, to confirm the safety and efficacy of Asciminib in Indian patients with Ph+ CML-CP (without threonine-315 residue with isoleucine \[T315I\] mutation), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) and patients with Ph+ CML-CP with T315I mutation.
Conditions
- Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Interventions
AsciminibDrug
Film-coated tablets with 40 mg dose strength taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of adverse events(AEs)/serious AEs (SAEs) in participants with Ph+ CML-CP without T315I mutationTime frame: up to 6 months
- Frequency and severity of AEs/SAEs in participants with Ph+ CML-CP with T315I mutationTime frame: up to 6 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Cuttack, India
Novartis Investigative Site
Guwahati, India
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Ahmedabad, Gujrat, India
Novartis Investigative Site
Bengaluru, Karnataka, India
Novartis Investigative Site
Trivandrum, Kerala, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.